Thoracic Cancer Trial
Non-Small Cell, Advanced
Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Physician and Research Staff Educational Material:
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Information and Assistance from the National Cancer Institute
- Locations and other information
- Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.
ClinicalTrials.gov ID: NCT04181060
Return to Home Page | Review Other Active Trials